(VIANEWS) – Apollo Commercial Real Estate Finance (ARI), Horace Mann Educators Corporation (HMN), Amgen (AMGN) are the highest payout ratio stocks on this list.
We have gathered information concerning stocks with the highest payout ratio so far. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. Apollo Commercial Real Estate Finance (ARI)
168.67% Payout Ratio
Apollo Commercial Real Estate Finance, Inc. operates as a real estate investment trust (REIT) that primarily originates, acquires, invests in, and manages commercial first mortgage loans, subordinate financings, and other commercial real estate-related debt investments in the United States. It is qualified as a REIT under the Internal Revenue Code. As a REIT, it would not be subject to federal income taxes, if the company distributes at least 90% of its REIT taxable income to its stockholders. Apollo Commercial Real Estate Finance, Inc. was founded in 2009 and is based in New York, New York.
Earnings Per Share
As for profitability, Apollo Commercial Real Estate Finance has a trailing twelve months EPS of $-0.06.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.33%.
Sales Growth
Apollo Commercial Real Estate Finance’s sales growth is negative 20% for the ongoing quarter and negative 12.7% for the next.
Volume
Today’s last reported volume for Apollo Commercial Real Estate Finance is 817818 which is 2.59% above its average volume of 797162.
Moving Average
Apollo Commercial Real Estate Finance’s worth is above its 50-day moving average of $10.21 and above its 200-day moving average of $10.42.
Yearly Top and Bottom Value
Apollo Commercial Real Estate Finance’s stock is valued at $10.78 at 04:23 EST, way under its 52-week high of $12.75 and way above its 52-week low of $8.58.
2. Horace Mann Educators Corporation (HMN)
94.78% Payout Ratio
Horace Mann Educators Corporation, together with its subsidiaries, operates as an insurance holding company in the United States. It operates in three segments: Property & Casualty, Life & Retirement, and Supplemental & Group Benefits. The company underwrites and markets personal lines of property and casualty insurance, including personal lines auto and property insurance products; supplemental insurance products, which include cancer, heart, hospital, supplemental disability, and accident coverages; retirement products, such as tax-qualified fixed and variable annuities; and life insurance products comprising whole life and term, as well as indexed universal life insurance products. It also offers student loan solutions, including online student loan management accounts for educators. The company markets its products through its sales force of full-time exclusive agents to K-12 teachers, administrators, and other employees of public schools and their families. Horace Mann Educators Corporation was founded in 1945 and is headquartered in Springfield, Illinois.
Earnings Per Share
As for profitability, Horace Mann Educators Corporation has a trailing twelve months EPS of $-0.8.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.16%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 681.8% and 252.2%, respectively.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Sep 13, 2023, the estimated forward annual dividend rate is 1.32 and the estimated forward annual dividend yield is 3.96%.
Sales Growth
Horace Mann Educators Corporation’s sales growth is 13.6% for the ongoing quarter and 8.1% for the next.
3. Amgen (AMGN)
59.25% Payout Ratio
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Earnings Per Share
As for profitability, Amgen has a trailing twelve months EPS of $14.06.
PE Ratio
Amgen has a trailing twelve months price to earnings ratio of 19.21. Meaning, the purchaser of the share is investing $19.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 133.8%.
Previous days news about Amgen (AMGN)
- According to Zacks on Monday, 4 December, "Among some other companies, Amgen (AMGN Quick QuoteAMGN – Free Report) has maridebart cafraglutide, also a GLP-1 receptor, in its pipeline that is being studied in a phase II study for treating obesity. "
4. Comp Energetica de Minas Gerais (CIG)
49.17% Payout Ratio
Companhia Energética de Minas Gerais, through its subsidiaries, engages in the generation, transmission, distribution, and sale of energy in Brazil. As of December 31, 2020, the company operated 89 hydroelectric, wind, and solar plants with an installed capacity of 6,000 MW; 339,086 miles of distribution lines; and as of January 27, 2021, it operated 4,374 miles of transmission lines. It is also involved in the acquisition, transportation, and distribution of gas and its sub products and derivatives; provision of cloud solution, IT infrastructure, IT management, and cybersecurity services; provision of technology systems and systems for operational management of public service concessions; sale and trading of energy; provision of telecommunications services; and distributed generation, account services, cogeneration, energy efficiency, and supply and storage management activities. The company was incorporated in 1952 and is headquartered in Belo Horizonte, Brazil.
Earnings Per Share
As for profitability, Comp Energetica de Minas Gerais has a trailing twelve months EPS of $0.49.
PE Ratio
Comp Energetica de Minas Gerais has a trailing twelve months price to earnings ratio of 4.53. Meaning, the purchaser of the share is investing $4.53 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.24%.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of $1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, 1’s stock is considered to be overbought (>=80).
Volatility
1’s last week, last month’s, and last quarter’s current intraday variation average was 1.00%, 1.00%, and 1.00%.
1’s highest amplitude of average volatility was 1.00% (last week), 1.00% (last month), and 1.00% (last quarter).
